Abstracts tagged "Patient reported outcomes"

Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Courtney Stull¹, Soumya Reddy², M. Elaine Husni³, Jose Scher⁴, Ethan Craig¹, Jessica Walsh⁵ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Cleveland Clinic, Cleveland, OH, ⁴NYU School of Medicine, New York City, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…
Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Kevin Kennedy¹, Emily Sirotich², Salman Surangiwala³, Maggie Larche², Mitchell Levine¹ and Jonathan Hausmann⁴, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…
Abstract Number: 1126 • ACR Convergence 2020
A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study
Dana DiRenzo¹, Carly Hunt², Erica Sibinga², Neda Gould², Ami Shah³, Susan Bartlett⁴ and Clifton Bingham III¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴McGill University, Montreal, Canada
Background/Purpose: Mindfulness Based Interventions (MBIs) are well-established self-management programs shown to be beneficial for pain, depression, and anxiety that focus on learning how to respond…
Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Gerd Burmester¹, Laure Gossec², Hubert van Hoogstraten³, Amy Praestgaard⁴, Gregory St John⁵, Thomas Huizinga⁶, Daniel Aletaha⁷ and Roy Fleischmann⁸, ¹Charité University Hospital Berlin, Berlin, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…
Abstract Number: 1469 • ACR Convergence 2020
Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
Jonathan Hausmann¹, Kevin Kennedy², Salman Surangiwala³, Maggie Larche⁴, Mitchell Levine², Jean Liew⁵, Zachary Wallace⁶ and Emily Sirotich⁴, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Washington, Seattle, WA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with rheumatic diseases are at increased risk of infection due to immune dysregulation and the use of immunosuppression. It is unknown whether they…
Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³, Minako Sato⁴, Masaru Tanaka⁴, Katsunori Ikari¹, Atsuo Taniguchi¹, Hisashi Yamanaka⁵ and Masayoshi Harigai⁶, ¹Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…
Abstract Number: PP08 • ACR Convergence 2020
Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up
Carly Harrison¹, Rashmi Sinha², Emily Sirotich³, Naira Ikram⁴, Kristen Young⁵, Christele Felix¹, Karen Durrant⁶, Richard Beesley⁷, Serena Mingolla⁸, Ana Isabel Martín Mancheño⁹, Dawn Richards¹⁰, Evelyn Olmedo¹¹, Wendy Costello¹², Monique Gore-Massy¹³, Laurie Proulx¹⁴, Maria Marino¹⁵ and Richard Howard¹⁶, ¹LupusChat, New York, NY, ²Systemic JIA Foundation, Cincinnati, OH, ³LA Lupus Lady, Hamilton, ON, Canada, ⁴Duke University, Austin, TX, ⁵Phoenix, AR, ⁶Autoinflammatory Alliance, San Francisco, CA, ⁷Juvenile Arthritis Research, United Kingdom, ⁸Associazione Nazionale Persone con Malattie Reumatolgiche e Rare APMARR APS, Brindisi, Italy, ⁹CEADE, Madrid, Spain, ¹⁰Canadian Arthritis Patient Alliance, Toronto, ON, Canada, ¹¹Buenos Aires, El Salvador, ¹²iCAN, Bansha, Tipperary, Ireland, ¹³Lupus Foundation of America, Brooklyn, NY, ¹⁴Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ¹⁵Arthritis Foundation; Vectra, Athens, GA, ¹⁶Spondylitis Association of America, Van Nuys, CA
Background/Purpose: The COVID-19 Global Rheumatology Alliance (GRA) is a volunteer-driven organization that originated in response to the global pandemic. It was created to improve patient…
Abstract Number: 0135 • ACR Convergence 2020
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Beth Schneider¹ and Eric Peacock¹, ¹MyHealthTeams, San Francisco, CA
Background/Purpose: Understanding patient satisfaction with their rheumatologist and the drivers of satisfaction is crucial to improving doctor-patient interactions, helping patients get on the right treatment…
Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…
Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Peter Hur⁵, Nina Kim⁶ and Kaleb Michaud⁷, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁷FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 1127 • ACR Convergence 2020
Association of Health Literacy and Numeracy with Patient Reported Psychological Outcomes
Mithu Maheswaranathan¹, Jennifer Rogers², Amanda Eudy¹, Kai Sun¹, Stacy Bailey³, S. Nicole Hastings¹ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Northwestern University, Chapel Hill, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Over 33 percent of American adults have low health literacy, which limits their ability to understand basic health information and make healthcare decisions. A…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1488 • ACR Convergence 2020
Application of the Knee Injury and Osteoarthritis Outcome Score Percentile Curves on Preoperative and up to 2 Years Postoperative Data of Patients Undergoing Total Knee Arthroplasty
Marieke Loef¹, Maaike G. Gademan¹, Daisy A. J. Latijnhouwers¹, Herman Kroon¹, Herman Kaptijn², Willem Marijnissen³, Rob G. H. Nelissen¹, Thea Vliet Vlieland⁴ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LangeLand Hospital, Zoetermeer, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Leiden University Medical Center, 2300 RC Leiden, Netherlands
Background/Purpose: The interpretation of patient-reported outcomes, such as the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire, can prove difficult if benchmarks are lacking. Therefore,…
Abstract Number: 1730 • ACR Convergence 2020
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Leonard Calabrese¹, Michael Weinblatt², Nancy Shadick², Cecilie Hegaard Brahe³, Mikkel Østergaard⁴, Merete Hetland⁵, Megan Horton⁶, Darl Flake⁶ and Eric Sasso⁷, ¹Cleveland Clinic, Cleveland, OH, ²Brigham and Women's Hospital, Boston, MA, ³Center for Rheumatology and Spine diseases, Glostrup, Denmark, ⁴Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶Myriad Genetics, Inc., Salt Lake City, UT, ⁷Myriad Autoimmune, South San Francisco, CA
Background/Purpose: To compare the abilities of MBDA score, patient global assessment (PGA) and evaluator global assessment (EGA) to assess risk for radiographic progression (RP), and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].